Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 13/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1423476 | 0.88 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL1424203 | 0.87 | GRIA2 (0.77) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423846 | 0.87 | GRIA2 (0.76) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4746431 | 0.85 | GRIA2 (1.00) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423601 | 0.81 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423692 | 0.81 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL1423687 | 0.80 | GRIA2 (0.77) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL1423665 | 0.79 | GRIA2 (0.78) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL4746459 | 0.75 | GRIA2 (0.80) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL3813509 | 0.75 | GRIA2 (0.67) | GRIA2CYP2C9CYP1A2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | claimed |
| EP-2086643-B1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| WO-2008053031-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137276-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GRIN1, GRM2, GRIN3A | GRIA2 23/4885CYP2C9 2591/4885CYP1A2 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.